Scinopharm Taiwan (TPE:1789) EV-to-EBIT : 36.23 (As of May. 29, 2025)

Scinopharm Taiwan EV-to-EBIT Chart

Scinopharm Taiwan Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBIT		Get a 7-Day Free Trial					51.65	51.54	36.91	49.02	33.12

Scinopharm Taiwan Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															38.30	38.47	34.16	33.12	46.78

Competitive Comparison of Scinopharm Taiwan's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinopharm Taiwan's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's EV-to-EBIT falls into.

Scinopharm Taiwan EV-to-EBIT Calculation

Scinopharm Taiwan's EV-to-EBIT for today is calculated as:

Scinopharm Taiwan's current Enterprise Value is NT$11,002 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan  (TPE:1789) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Scinopharm Taiwan's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Scinopharm Taiwan's Enterprise Value for the quarter that ended in Mar. 2025 was NT$14,205 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinopharm Taiwan Business Description